Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

Light chain-associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal immunoglobulin (Ig) light chains form amyloid fibrils. There is considerable heterogeneity in clinical presentation, and prognosis of the disease relates to the severity of organ dysfunction induced by amyloid deposits. The mechanisms by which the amyloid fibrils are deposited as well as the predilection for specific organ sites have not been clearly elucidated. This study characterizes the repertoire of immunoglobulin light chain variable genes used by the clonal B cell in AL amyloid patients, and the association of light chain variable region (VL) genes with clinical presentation and outcome is assessed in 58 (32 lambda and 26 kappa) patients. A preferential use of VL germ-line genes was noted for both AL kappa and lambda patients. There was a significant correlation between the use of the Vlambda VI germ-line donor, 6a, and renal involvement as well as the Vlambda III gene, 3r, with soft-tissue AL. The use of a biased VL gene repertoire also correlated with clinical outcome, revealing important trends for predicting prognosis. The use of Vlambda II germ-line genes was associated with cardiac amyloidosis and affected survival adversely. The presence of multiple myeloma also correlated with a poor prognosis. The presence of renal disease, on the other hand, was associated with improved survival. Therefore, identification of the clonal VL gene in AL has important implications in determining clinical outcome.

[1]  M. Skinner,et al.  Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid‐related organ involvement and survival after stem cell transplantation , 1999, British journal of haematology.

[2]  T. Therneau,et al.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.

[3]  M. Gertz,et al.  The periarteriolar lymphocyte sheath in immunodeficiency T- or B-lymphocyte area? , 1990 .

[4]  A. Solomon,et al.  Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. , 1994, Clinical immunology and immunopathology.

[5]  E. Arbustini,et al.  Evidence that amyloidogenic light chains undergo antigen-driven selection. , 1998, Blood.

[6]  P. T. Jones,et al.  The creation of diversity in the human immunoglobulin Vλ repertoire , 1997 .

[7]  L. Benson,et al.  Trimolecular Complexes of λ Light Chain Dimers in Serum of a Patient with Multiple Myeloma , 2002 .

[8]  C. Martínez,et al.  The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. , 2001, Blood.

[9]  S. Quaglini,et al.  The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. , 1999, Haematologica.

[10]  S M Breathnach,et al.  Amyloid and amyloidosis. , 1988, Journal of the American Academy of Dermatology.

[11]  S. Dübel,et al.  Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. , 1995, Journal of immunological methods.

[12]  M. Schiffer,et al.  Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology. , 1991, Biochemistry.

[13]  T. Therneau,et al.  Long-term survival (10 years or more) in 30 patients with primary amyloidosis. , 1999, Blood.

[14]  A. Khamlichi,et al.  Primary structure of a monoclonal κ chain in myeloma with light chain deposition disease , 1992 .

[15]  J. Seward,et al.  Echocardiographic features of amyloid ischemic heart disease. , 1985, The American journal of cardiology.

[16]  E. Ascari,et al.  Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment , 2002 .

[17]  Kyle Ra,et al.  Amyloidosis (AL). Clinical and laboratory features in 229 cases. , 1983 .

[18]  A. Linos,et al.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. , 1992, Blood.

[19]  M. Stone,et al.  Amyloidosis: a final common pathway for protein deposition in tissues. , 1990, Blood.

[20]  A. Solomon,et al.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). , 1982, The Journal of clinical investigation.

[21]  R. Kyle,et al.  Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. , 1988, The American journal of medicine.

[22]  A. Feeney,et al.  E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. , 2000, Molecular cell.

[23]  A. Feeney,et al.  Localized Gene-Specific Induction of Accessibility to V(D)j Recombination Induced by E2a and Early B Cell Factor in Nonlymphoid Cells , 2001, The Journal of experimental medicine.

[24]  R. Kyle,et al.  Hepatic amyloidosis: Clinical appraisal in 77 patients , 1997, Hepatology.

[25]  A. Rich.  Linus Pauling: Chemist and Molecular Biologist , 1995, Annals of the New York Academy of Sciences.

[26]  R. Kyle,et al.  Primary systemic amyloidosis--a diagnostic primer. , 1989, Mayo Clinic proceedings.

[27]  Yang Zhang,et al.  Mobilized CD34+ cells selected as autografts in patients with primary light‐chain amyloidosis: rationale and application , 1998, Transfusion.

[28]  R. Falk,et al.  Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. , 1996, The American journal of medicine.

[29]  M. Pras,et al.  Idiopathic AL-kiv amyloidosis presenting as giant hepatomegaly. , 1982, Israel journal of medical sciences.

[30]  R. Falk,et al.  Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. , 1998, Blood.

[31]  M. Schiffer,et al.  Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light‐chain amyloid proteins , 1994, Protein science : a publication of the Protein Society.

[32]  J. Seward,et al.  Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. , 1984, Mayo Clinic proceedings.

[33]  P. Lipsky,et al.  Molecular Mechanisms and Selection Influence the Generation of the Human VλJλ Repertoire , 1999, The Journal of Immunology.

[34]  H. Zachau,et al.  Expression and Hypermutation of Human Immunoglobulin k Genes a , 1995 .

[35]  M. Cogné,et al.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. , 1991, The Journal of clinical investigation.

[36]  L. Foroni,et al.  Variable kappa gene rearrangement in lymphoproliferative disorders: an analysis of V kappa gene usage, VJ joining and somatic mutation. , 1994, Leukemia.

[37]  K. Sletten,et al.  Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. , 2001, American journal of clinical pathology.

[38]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[39]  R. Wetzel.  Domain stability in immunoglobulin light chain deposition disorders. , 1997, Advances in protein chemistry.